Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Amortization of Deferred Charges (2018 - 2025)

Historic Amortization of Deferred Charges for Guided Therapeutics (GTHP) over the last 8 years, with Q3 2025 value amounting to $54000.0.

  • Guided Therapeutics' Amortization of Deferred Charges rose 14545.45% to $54000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $210000.0, marking a year-over-year increase of 10000.0%. This contributed to the annual value of $93000.0 for FY2024, which is 2846.15% down from last year.
  • Guided Therapeutics' Amortization of Deferred Charges amounted to $54000.0 in Q3 2025, which was up 14545.45% from $68000.0 recorded in Q2 2025.
  • Guided Therapeutics' Amortization of Deferred Charges' 5-year high stood at $172000.0 during Q2 2021, with a 5-year trough of $14000.0 in Q3 2021.
  • Its 5-year average for Amortization of Deferred Charges is $46052.6, with a median of $33000.0 in 2022.
  • In the last 5 years, Guided Therapeutics' Amortization of Deferred Charges tumbled by 8640.78% in 2021 and then surged by 27777.78% in 2025.
  • Over the past 5 years, Guided Therapeutics' Amortization of Deferred Charges (Quarter) stood at $70000.0 in 2021, then tumbled by 54.29% to $32000.0 in 2022, then rose by 3.12% to $33000.0 in 2023, then plummeted by 36.36% to $21000.0 in 2024, then surged by 157.14% to $54000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $54000.0 for Q3 2025, versus $68000.0 for Q2 2025 and $67000.0 for Q1 2025.